Skip to content

Effect of dietary fiber intake on enteric bacteria of patients with inflammatory bowel disease and irritable bowel syndrome.

Effect of dietary fiber intake on enteric bacteria of patients with inflammatory bowel disease and irritable bowel syndrome. - Effect of dietary fiber ingestion on enteric bacteria.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000037537
Enrollment
300
Registered
2019-09-05
Start date
2019-09-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult, and patients with inflammatory bowel disease and irritable bowel syndrome.

Interventions

Oral intake of water-soluble dietary fiber (continuous, up to 6 month)

Sponsors

Watanabe Hsopital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Japanese male and female volunteers (20 to 80 years old) 2) Healthy volunteer 3) Patents with inflammatory bowel disease and irritable bowel syndrome. 4) Who has received sufficient explanation about the contents and purpose of the study by the document, and has the ability to understand the informed consent with voluntary participation.

Exclusion criteria

Exclusion criteria: 1) Who does not give consent. 2) Who is difficult to collect feces 3) Wo has blood contamination in stool. 4) Who is judged that systemic symptom is bad. 5) Who is in breast-feeding or pregnancy, or wishes to become pregnant during the study period. 6) Who has obstruction or stenosis of the gastrointestinal tract, or those prone to gastrointestinal obstruction. 7) Who have been ill in the past due to the ingestion of water-soluble dietary fiber. 8) Who is poor-self-determination ability, dementia, etc. 9) Who is judged as ineligible by principal investigators or researchers.

Design outcomes

Primary

MeasureTime frame
Bowel-flora alteration

Secondary

MeasureTime frame
Serum chemistry, clinical manifestation, and colonoscopy at0,2,4 and 6 month after investigation.

Countries

Japan

Contacts

Public ContactKoichiro Tsuchiya

Tokushima University Faculty of Pharmacy

tsuchiya@tokushima-u.ac.jp088-633-7250

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026